Associated Papers
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
Mezquita L et al.
British Journal of Cancer, 2024
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Orditura M et al.
Breast (edinburgh, Scotland), 2018
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).
Ku BM et al.
Journal of Pathology and Translational Medicine, 2018
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD et al.
Genome Medicine, 2017
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.
Kaisaki PJ et al.
Plos One, 2016
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.
Saito T et al.
International Journal of Clinical and Experimental Pathology, 2015
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K et al.
Medical Oncology (northwood, London, England), 2014
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
Fang S et al.
Drug Design, Development and Therapy, 2014
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Co-conserved features associated with cis regulation of ErbB tyrosine kinases.
Mirza A et al.
Plos One, 2010